Published in Neurology on June 25, 2002
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol (2010) 2.19
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 2.00
The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.93
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82
Neuropsychological assessment of dementia. Annu Rev Psychol (2009) 1.76
Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs (2010) 1.72
The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med (2012) 1.66
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration. Neurology (2008) 1.48
Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis. Neuropsychology (2009) 1.35
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
The early neuropsychological and behavioral characteristics of frontotemporal dementia. Neuropsychol Rev (2008) 1.25
Qualitative neuropsychological performance characteristics in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.25
Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One (2011) 1.24
Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. J Neurol Neurosurg Psychiatry (2007) 1.22
Frontotemporal dementias: a review. Ann Gen Psychiatry (2007) 1.11
Functional neuroimaging and presenting psychiatric features in frontotemporal dementia. J Neurol Neurosurg Psychiatry (2005) 1.11
Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia (2010) 1.07
Changes in cognition. Neurobiol Aging (2011) 1.06
Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. J Int Neuropsychol Soc (2008) 1.03
Visual spatial cognition in neurodegenerative disease. Neurocase (2010) 1.03
Predicting functional decline in behavioural variant frontotemporal dementia. Brain (2011) 1.00
Emotion regulation deficits in frontotemporal lobar degeneration and Alzheimer's disease. Psychol Aging (2010) 1.00
Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. J Int Neuropsychol Soc (2009) 0.96
Mutual gaze in Alzheimer's disease, frontotemporal and semantic dementia couples. Soc Cogn Affect Neurosci (2010) 0.94
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity. PLoS One (2010) 0.93
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. Am J Pathol (2013) 0.92
Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates. Cell Death Differ (2014) 0.91
The frontal-anatomic specificity of design fluency repetitions and their diagnostic relevance for behavioral variant frontotemporal dementia. J Int Neuropsychol Soc (2012) 0.90
MMSE scores decline at a greater rate in frontotemporal degeneration than in AD. Dement Geriatr Cogn Disord (2006) 0.88
Baseline predictors of clinical progression among patients with dysexecutive mild cognitive impairment. Dement Geriatr Cogn Disord (2010) 0.86
Language, executive function and social cognition in the diagnosis of frontotemporal dementia syndromes. Int Rev Psychiatry (2013) 0.83
The Extension of the German CERAD Neuropsychological Assessment Battery with Tests Assessing Subcortical, Executive and Frontal Functions Improves Accuracy in Dementia Diagnosis. Dement Geriatr Cogn Dis Extra (2014) 0.82
Different apathy profile in behavioral variant of frontotemporal dementia and Alzheimer's disease: a preliminary investigation. Curr Gerontol Geriatr Res (2012) 0.82
Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology (2016) 0.80
Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration. Int Rev Psychiatry (2013) 0.79
Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. J Mol Neurosci (2011) 0.78
Patient care and management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 0.78
α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet (2016) 0.77
Biomarkers in frontotemporal lobar degeneration. Curr Opin Neurol (2010) 0.76
Biomarkers in the primary progressive aphasias. Aphasiology (2014) 0.75
Frontotemporal dementia: clinical, neuropsychological, and neuroimaging description. Colomb Med (Cali) (2014) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
Conservation conflicts across Africa. Science (2001) 7.09
Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 6.58
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Symmetry and transitivity of conditional relations in monkeys (Cebus apella) and pigeons (Columba livia). J Exp Anal Behav (1985) 5.02
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology (1990) 3.79
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci (1997) 3.61
Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology (1997) 3.53
Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment (1999) 3.47
Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci (2000) 3.40
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology (2003) 3.07
Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol (1992) 3.04
A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology (2000) 2.76
Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. J Neurosci (1988) 2.73
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology (1995) 2.69
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol (2000) 2.37
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging (2008) 2.31
In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology (2007) 2.24
Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol (1990) 2.24
Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology (2005) 2.18
Neocortical cell counts in normal human adult aging. Ann Neurol (1987) 2.16
Cognitive and functional status of the oldest old. J Am Geriatr Soc (1996) 2.14
Rehabilitation of hemiparesis after stroke with a mirror. Lancet (1999) 2.13
Acute ascending necrotizing myelopathy caused by herpes simplex virus type 2. Neurology (1987) 2.11
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology (2000) 2.10
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn (1992) 1.98
Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology (1998) 1.96
A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol (1988) 1.96
Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS (2000) 1.93
Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology (2000) 1.91
Word repetition in amnesia. Electrophysiological measures of impaired and spared memory. Brain (2000) 1.90
Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol (1994) 1.90
Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett (1989) 1.89
The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology (1993) 1.89
Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage (2008) 1.87
The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology (2004) 1.87
Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol (1987) 1.85
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature (1993) 1.85
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol (2001) 1.84
Semantic memory impairment in Alzheimer's disease: failure of access or degraded knowledge? Neuropsychologia (1992) 1.82
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.80
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles. J Neuropathol Exp Neurol (1987) 1.78
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology (2004) 1.74
Alzheimer's disease can be accurately diagnosed in very mildly impaired individuals. Neurology (2002) 1.74
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med (2000) 1.71
Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol (2000) 1.69
Essential role of neocortical acetylcholine in spatial memory. Nature (1995) 1.68
Late onset dementia with argyrophilic grains and subcortical tangles or atypical progressive supranuclear palsy? Ann Neurol (1991) 1.67
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2007) 1.67
Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol Aging (1999) 1.66
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology (1996) 1.64
Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology (2011) 1.60
Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging (1990) 1.58
Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology (1997) 1.58
Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 1.58